13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET)

Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET)

Unlike intermittent hemodialysis, which produces cyclical peaks and troughs in solute concentrations, Peritoneal Dialysis (PD) provides continuous, gentle solute clearance and steady-state fluid removal. In PD, the patient's living peritoneal membrane serves as the semipermeable dialysis filter. Peritoneal microvascular endothelial cells, the interstitial matrix, and the mesothelial cellular lining form the three-pore biological barrier across which water and dissolved solutes diffuse.

Assessing dialysis adequacy in PD requires measuring total weekly small solute removal (combining peritoneal clearance with native kidney excretion) and evaluating the transport characteristics of the peritoneal membrane. The Peritoneal Equilibration Test (PET) provides the physiological blueprint for matching the patient's individual peritoneal membrane transport rate to an appropriate dialytic regimen and nutritional prescription.

---

Peritoneal Dialysis Adequacy: The Weekly $Kt/V$ Target

Because peritoneal dialysis operates continuously 24 hours per day, 7 days per week, adequacy is not calculated on a per-treatment basis. Instead, it is expressed as Total Weekly $Kt/V_{urea}$, representing the cumulative fractional clearance achieved over seven consecutive days:

$\text{Total Weekly } Kt/V = \text{Peritoneal } Kt/V + \text{Renal } Kt/V (rKt/V)$

Clinical Clearance Targets (KDOQI & ISPD Guidelines)

• Target Clearance: KDOQI (2006) set a minimum delivered total weekly $Kt/V_{urea}$ of 1.7 for both CAPD and APD, and the CMS plan-of-care standard uses the same value. ISPD's 2020 practice recommendations favor goal-directed, person-centered prescriptions and discourage using small-solute clearance as a stand-alone target.
• Evidence-Based Evolution: Earlier guidance recommended weekly $Kt/V$ targets of about 2.0 for CAPD and higher for APD, based partly on the observational CANUSA cohort. Randomized trials, the ADEMEX trial (ADEquacy of PD in MEXico, 2002) and a Hong Kong trial (2003), then showed that raising peritoneal small-solute clearance did not improve survival, and a CANUSA reanalysis found that the survival benefit came from residual kidney function rather than peritoneal clearance.
• Holistic Adequacy Concept: Modern ISPD guidelines emphasize that $Kt/V$ must not be evaluated in isolation. True PD adequacy encompasses clinical well-being, euvolemia (absence of peripheral edema, normal blood pressure), correction of electrolyte and acid-base disturbances, absence of uremic symptoms, and preservation of nutritional status.

24-Hour Specimen Collection Protocol

Calculating total weekly $Kt/V$ requires simultaneous 24-hour dialysate effluent and 24-hour urine collection:

$\text{Peritoneal } Kt/V = \frac{D_{urea} \times V_d}{P_{urea} \times V_B} \times 7$

$\text{Renal } Kt/V = \frac{U_{urea} \times V_u}{P_{urea} \times V_B} \times 7$

Where $D_{urea}$, $U_{urea}$, and $P_{urea}$ represent urea nitrogen concentrations in dialysate effluent, urine, and plasma; $V_d$ is 24-hour drained dialysate volume (L); $V_u$ is 24-hour urine volume (L); and $V_B$ is total body water (L).

---

Residual Kidney Function (RKF): The Prognostic Lifeline

In peritoneal dialysis, Residual Kidney Function (RKF) is an extraordinarily powerful predictor of patient longevity and technique success. Re-analysis of the CANUSA study revealed that the clinical survival advantage initially attributed to total $Kt/V$ was driven entirely by residual renal clearance rather than peritoneal clearance.

Calculating Residual Glomerular Filtration Rate (rGFR / KrGFR)

Residual kidney function is formally quantified as the mean of 24-hour urinary urea and creatinine clearances:

$\text{rGFR} = \frac{\text{Urea Clearance} + \text{Creatinine Clearance}}{2}$

$\text{Urea Clearance (mL/min)} = \frac{U_{urea} (\text{mg/dL}) \times V_u (\text{mL})}{P_{urea} (\text{mg/dL}) \times 1440 \text{ min}}$

$\text{Creatinine Clearance (mL/min)} = \frac{U_{cr} (\text{mg/dL}) \times V_u (\text{mL})}{P_{cr} (\text{mg/dL}) \times 1440 \text{ min}}$

Why average both clearances? In failing native kidneys, proximal tubules actively secrete creatinine into the urine, which falsely inflates creatinine clearance above the true GFR. Conversely, tubular reabsorption of urea falsely depresses urea clearance below true GFR. Averaging the two clearances cancels these opposing errors, providing an accurate representation of inulin-equivalent GFR.

Clinical and Nutritional Superiority of Native RKF

1. Continuous Native Clearance: Endogenous nephrons clear middle molecules, protein-bound uremic toxins (indoxyl sulfate, p-cresyl sulfate), and advanced glycation end-products far more effectively than artificial peritoneal diffusion.
2. Enhanced Mineral & Fluid Excretion: Even modest residual urine output ($>500\text{ mL/day}$) dramatically simplifies dietary fluid and sodium management and improves dietary phosphorus excretion.
3. Nephrotoxic Avoidance Mandate: Preserving RKF requires absolute avoidance of nephrotoxic medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and aminoglycosides, minimization of iodinated radiocontrast, and aggressive prevention of dehydration or peritonitis-induced septic episodes.
4. Incremental Peritoneal Dialysis: Patients with substantial RKF (rGFR $>5\text{ mL/min}$ and urine output $>1,000\text{ mL/day}$) can initiate therapy with reduced daily dialytic exchanges (e.g., 2–3 dwells/day rather than 4–5), reducing peritoneal glucose exposure and extending peritoneal membrane longevity.

---

The Standardized Peritoneal Equilibration Test (PET)

Introduced by Zbylut Twardowski in 1987, the Peritoneal Equilibration Test (PET) is the standardized diagnostic test used worldwide to characterize the intrinsic transport properties of the peritoneal membrane. The PET evaluates solute transport across the peritoneum over a standardized 4-hour dwell using 2.0 liters of 2.5% dextrose dialysate.

Standardized PET Testing Procedure

1. Pre-test Preparation: The patient undergoes a standard 8- to 12-hour overnight dwell immediately preceding the test. The overnight dwell is completely drained over 20 minutes in the upright position.
2. Infusion Phase: Exactly 2.0 liters of fresh, pre-warmed 2.5% dextrose dialysate is infused into the peritoneal cavity over 10 minutes ($t = 0$).
3. Baseline Sampling ($t = 0$): Immediately after infusion, 200 mL of dialysate is drained, 10 mL is collected for baseline analysis ($D_0$), and the remaining 190 mL is re-infused.
4. Midpoint Sampling ($t = 2\text{ hours}$): At 2 hours, 200 mL of dialysate is drained, a 10 mL aliquot is collected ($D_2$), 190 mL is re-infused, and a concurrent venous blood sample is drawn to measure plasma creatinine and glucose ($P$).
5. Completion Phase ($t = 4\text{ hours}$): At 4 hours, the patient drains the peritoneal cavity completely over 20 minutes in the sitting position. The total drain volume is measured, mixed thoroughly, and a 10 mL sample is collected ($D_4$).
6. Laboratory Correction: Dialysate creatinine concentrations must be corrected for glucose interference in the alkaline picrate (Jaffe) assay, as high dialysate glucose falsely reacts as creatinine.

---

The Four Peritoneal Transporter Categories

By plotting the 4-hour dialysate-to-plasma creatinine ratio ($D/P\ Cr$) and the 4-hour dialysate glucose relative to initial glucose ($D/D_0\ \text{glucose}$), patients are classified into one of four transport categories:

┌────────────────────────────────────────────────────────────────────────┐
│                     PET Solute Equilibration Dynamics                  │
├────────────────────────────────────────────────────────────────────────┤
│  D/P Creatinine Ratio                   D/D0 Glucose Ratio             │
│  1.0 ┌──────────────────────┐          1.0 ┌──────────────────────┐    │
│      │        High          │              │         Low          │    │
│  0.81├──────────────────────┤         0.49 ├──────────────────────┤    │
│      │    High-Average      │              │     Low-Average      │    │
│  0.65├──────────────────────┤         0.38 ├──────────────────────┤    │
│      │     Low-Average      │              │     High-Average     │    │
│  0.50├──────────────────────┤         0.26 ├──────────────────────┤    │
│      │         Low          │              │         High         │    │
│  0.0 └──────────────────────┘          0.0 └──────────────────────┘    │
│       (Solute Equilibration)                (Osmotic Gradient Decay)   │
└────────────────────────────────────────────────────────────────────────┘

Clinical Management of the High Transporter

Patients classified as High (Fast) Transporters present unique clinical and nutritional challenges:

1. Ultrafiltration Failure on Long Dwells: Because small pores allow rapid solute flux, glucose is absorbed swiftly from the dialysate into systemic blood ($D/D_0 < 0.26$). The osmotic gradient dissipates within 2 to 3 hours. If left indwelling for 6 to 10 hours (such as a standard daytime dwell in APD or overnight dwell in CAPD), the osmotic gradient reverses, leading to dialysate reabsorption into the blood and fluid overload.
2. Icodextrin Solution: To achieve sustained daytime ultrafiltration without glucose toxicity, high transporters should be prescribed 7.5% icodextrin for long dwells. Icodextrin is a high-molecular-weight glucose polymer derived from starch that generates continuous colloid osmosis via peritoneal inter-endothelial clefts, sustaining ultrafiltration for 8 to 16 hours.
3. Peritoneal Protein Leakage: The highly porous peritoneal membrane in fast transporters results in substantial daily peritoneal protein losses, often exceeding 10 to 15 grams per day (predominantly albumin and immunoglobulins). To prevent severe hypoalbuminemia and protein-energy wasting, the renal dietitian should ensure intake of at least 1.0–1.2 g/kg/day (KDOQI 2020) and individualize upward when measured losses are large.
4. Glucometer Cross-Reactivity Alert: When patients use icodextrin, circulating icodextrin metabolites (primarily maltose) interfere with glucose dehydrogenase pyrroloquinoline quinone (GDH-PQQ) and glucose-dye-oxidoreductase blood glucose test strips. This produces falsely elevated blood glucose readings, which can lead to inappropriate insulin administration, resulting in life-threatening hypoglycemic coma. Dietitians and patients must verify that glucometers utilize glucose-specific methods (such as glucose dehydrogenase flavin-adenine dinucleotide [GDH-FAD] or hexokinase).